Anteo negotiates revised terms

Company News

Anteo Diagnostics Limited (ASX:ADO) has emerged from a trading halt to announce revised terms for its acquisition of DIAsource ImmunoAssays in Belgium. 
The original deal was for a purchase price of $24 million with a 2 year earn out to vendors. The new deal is for 50 per cent of the purchase price in cash up front and the remainder via a deferred payment plan. 
The acquisition extends Anteo’s capabilities in the in vitro diagnoses sector and provides a presence in 75 countries. 
Anteo reported a net loss of $4.2 million for the 2015 financial year. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.